IthaMaps

Welcome to IthaMaps

IthaMaps is a global epidemiology database of heamoglobinopathies, illustrating published data on a dynamic global to regional map. Country-specific information on haemoglobinopathy-related policies, prevalence, incidence and overall disease burden is given, including relative allele frequencies of specific globin mutations in each country and/or region, dynamically linked to corresponding IthaGenes entries.

IthaMaps content was supported by partnership with the HVP Global Globin 2020 Challenge

Search

Search Country:		OR	Search for:		Show organisations

Healthcare information:
Major haemoglobinopathies:

Mutation search

Select locus:		Select mutation:

More Fewer search options

General information for Afghanistan

Afghanistan

Continent:	Asia
Capital:	Kabul
Population:	29121286
Area (in sq km):	647500.0

Haemoglobinopathy-specific healthcare policy information for Afghanistan

Healthcare policy		Comment/Info	Reference
Prevention programme:	No	No carrier screening programme [From: 2nd MEGMA Conference Proceedings].	[PMID: 34130618]
SCD newborn screening:	No	From: 2nd MEGMA Conference Proceedings.
Prenatal screening:	No	Prenatal tests are inaccessible and unaffordable.	[PMID: 34130618]
Antenatal screening:	No	Services testing the blood of pregnant (thal) women are inaccessible and unaffordable.	[PMID: 34130618]
Haemoglobinopathies patient registry:	No	From: 2nd MEGMA Conference Proceedings.	[PMID: 34130618]
Dedicated treatment centres:	Yes (Regional)	E.g.: Meena Thalassaemia & Blood Transfusion Center, Kabul; STOP Thalassaemia center, Kabul.
Blood transfusion availability:	No	Limited access to regular and safe blood transfusions; no widely available blood screening to exclude HBV, HSV and HIV infection.	[PMID: 34130618]
Patient associations:	Yes (National)	E.g.: Meena Welfare Association (MWA) Afghanistan; Future for Afghanistan Children Organization.

Prevalence and incidence of major haemoglobinopathies in Afghanistan

Haemoglobinopathy		Comment/Info	Reference
Prevalence of β-thalassaemia carriers:	3 % of the population		[PMID: 24672827]
Expected incidence of β-thalassaemia:	283 expected affected births/year	From: 2nd MEGMA Conference Proceedings
Known β-thalassaemia patients:	3000 patients	Over 3000, an estimate figure by healthcare workers.	[PMID: 34130618]

Global Burden of Disease data for Afghanistan

Migration data for Afghanistan

Mutation frequencies in Afghanistan

No mutation frequencies are currently available for Afghanistan

Organisations in Afghanistan

Organisations in Afghanistan are currently not available

Microattributions

No microattibutions were provided for Afghanistan. Please contact us, if you are willing to review existing information or provide new data.

To provide new epidemiological information and/or report mistakes, please register/log in first or use the Contact Us form.

Important Note: The relative allele frequencies presented in IthaMaps are not calculated by ITHANET, but they are extracted from the corresponding publications. ITHANET is not responsible for any mistakes in the data. Please use this information with caution! We encourage scientists that have more detailed or updated epidemiological information to contact us.

Disclaimer: The information on this website is provided as an information resource only and must not to be used as a substitute for professional diagnosis and treatment. The ITHANET Portal and IthaMaps are not responsible or liable for any advice, course of treatment, diagnosis or any other information, services or products that an individual obtains through this website.

Note: The information you provide for the specific country will appear on the IthaMaps website and your contribution will be acknowledged.

Country:

Contributor's details

To be included in ITHANET Organisations & Experts

Name:		Organisation's name:
Surname:		Organisation's brief description:
Title:		Organisation's address:
Expertise/Research interests:		Organisation's City:
Address:		Organisation's Country:
City:		Organisation's website:
Country:		E-mail:
ORCID

Healthcare Policies

Health-policy	Select one Answer	Comment
Prevention programme
SCD newborn screening
Prenatal screening
Antenatal screening
Haemoglobinopathies patient registry
Rare disease patient registry
Dedicated treatment centres
Blood transfusion availability
Iron chelation availability
MRI facilities
Patient associations
Genetic counselling

Status of major Haemoglobinopathies

In Expected Incidence of β-thalassaemia and sickle cell disease please provide the number of expected affected births/year (without prevention).
In Incidence of β-thalassaemia and sickle cell disease please provide the number of affected births/year (after prevention).

Haemoglobinopathy	Provide value		Comment
Prevalence of β-thalassaemia carriers		% of the population
Prevalence of sickle cell disease carriers		% of the population
Prevalence of α-thalassaemia carriers		% of the population
Prevalence of Hb E carriers		% of the population
Prevalence of Hb C carriers		% of the population
Expected incidence of β-thalassaemia		expected affected births/year
Expected incidence of sickle cell disease		expected affected births/year
Expected incidence of α-thalassaemia		expected affected births/year
Incidence of β-thalassaemia		affected births/year
Incidence of sickle cell disease		affected births/year
Incidence of α-thalassaemia		affected births/year
Known β-thalassaemia patients		patients
Known sickle cell disease patients		patients

Mutation Frequencies

Please provide details about publications reporting mutation frequencies in the country of reference (either country-wide studies or region-specific studies).

Show on map:		Information to display:
Minimum sample size: